Mitsui & Co. Subsidiary, Xeureka, Launches Tokyo-1 Project Propelling AI-Driven Drug Discovery

February 01, 2024

TOKYO, JAPAN – February 1, 2024 – Xeureka Inc. (below “Xeureka”, President and CEO: Akiko Mutai), a subsidiary of Mitsui & Co., Ltd., officially commenced the full-scale operation of the “Tokyo-1 Project,” a groundbreaking initiative aimed at enhancing the efficiency of drug discovery research in Japan through the construction of a high-speed, high-capacity supercomputer and the provision of cutting-edge AI services. The launch signifies a significant step forward in accelerating pharmaceutical research within the country.

The Tokyo-1 Project is poised to contribute to the digital transformation of domestic pharmaceutical companies and enhance global competitiveness through its state-of-the-art AI supercomputer, drug discovery DX solutions, and information community. By connecting stakeholders in the life sciences sector involved with Tokyo-1, the project aims to promote collaborative research and knowledge sharing. Tokyo-1 aspires to become an innovation hub for drug discovery in Japan.

Key Features of Tokyo-1:

    1. Cutting-Edge AI Supercomputer: Tokyo-1 is built on Xeureka’s state-of-the-art AI supercomputer, build with NVIDIA DGX H100, harnessing the advanced capabilities of Xeureka’s computational simulations and AI system. It promises to deliver a next-generation approach surpassing the traditional boundaries of drug discovery.
    2. Advanced Drug Discovery DX Solutions: In addition to Xeureka’s large-scale simulations and AI-driven machine learning solutions, Tokyo-1 will showcase numerous advanced computational and AI solutions for drug discovery from domestic and international emerging AI companies. Tokyo-1 will contribute to improvements in both the efficiency of drug discovery research and successes rate in clinical development.
    3. Advanced Drug Discovery DX Solutions: Tokyo-1 will foster information exchange among participating members, providing international access to the latest results in cutting-edge research, and will organize collaborative workshops with leading companies from around the world. This initiative aims to contribute to more efficient and effective utilization of AI.

Company Profile of Xeureka Inc.

    • Head Office: 2-1, Otemachi 1-chome, Chiyoda-ku, Tokyo
    • Representative: Akiko Mutai, President and CEO
    • Established: November 1st, 2021
    • Shareholders: MITSUI & CO., LTD.
    • Business: Provide computational and AI drug discovery support services to pharmaceutical and biotechnology companies, Research and development for drug discovery through collaborative research
    • URL: https://xeureka.co.jp/en
BACK